Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
162.00    -1.50 (-0.93%)
Bid:
159.00
Ask:
162.00
Spread: 3.00 (1.887%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Result of AGM

27 Apr 2020 14:00

RNS Number : 0015L
Hutchison China Meditech Limited
27 April 2020
 

 

Results of Annual General Meeting

 

 

London: Monday, April 27, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 27, 2020 were duly passed. The poll results of the resolutions were as follows:

 

Number of Votes (%)*

 

Resolutions

 

For

 

 

Against

 

 

Withheld#

1

To consider and adopt the audited financial statements and the reports of the directors and independent auditor for the year ended 31 December 2019.

622,475,006

(99.97825%)

135,425

(0.02175%)

209,095

2(A)

To re-elect Mr Simon To as a director.

547,656,413

(93.79515%)

36,229,215

(6.20485%)

38,935,898

2(B)

To re-elect Mr Christian Hogg as a director.

614,200,226

(98.61822%)

8,605,840

(1.38178%)

15,460

 

2(C)

To re-elect Mr Johnny Cheng as a director.

612,394,636

(98.32808%)

10,412,825

(1.67192%)

14,065

 

2(D)

To re-elect Dr Weiguo Su as a director.

612,400,256

(98.32849%)

10,410,325

(1.67151%)

10,945

2(E)

To re-elect Dr Dan Eldar as a director.

612,014,066

(98.26647%)

10,796,615

(1.73353%)

10,845

2(F)

To re-elect Ms Edith Shih as a director.

612,006,786

(98.26611%)

10,798,775

(1.73389%)

15,965

2(G)

To re-elect Mr Paul Carter as a director.

620,440,741

(99.61989%)

2,367,325

(0.38011%)

13,460

 

2(H)

To re-elect Dr Karen Ferrante as a director.

622,577,316

(99.96253%)

233,365

(0.03747%)

10,845

2(I)

To re-elect Mr Graeme Jack as a director.

619,884,406

(99.53097%)

2,921,135

(0.46903%)

15,985

2(J)

To re-elect Professor Tony Mok as a director.

622,805,231

(99.99912%)

5,450

(0.00088%)

10,845

3

To re-appoint PricewaterhouseCoopers as the auditor of the Company and authorise the board of directors to fix the auditor's remuneration.

622,682,786

(99.97980%)

125,795

(0.02020%)

12,945

4

Ordinary Resolution No. 4(A)

:

To grant a general mandate to the directors of the Company to issue additional shares.

615,116,216

(98.76581%)

7,686,590

(1.23419%)

18,720

Special Resolution No. 4(B)

:

To disapply pre-emption rights (general power).

618,134,451

(99.25233%)

4,656,435

(0.74767%)

30,640

Special Resolution No. 4(C)

:

To disapply pre-emption rights (in connection with an equity raise).

529,841,459

(86.65474%)

81,598,207

(13.34526%)

11,381,860

Ordinary Resolution No. 4(D)

:

To grant a general mandate to the directors of the Company to repurchase shares of the Company.

622,786,026

(99.99584%)

25,890

(0.00416%)

9,610

5.

Ordinary Resolution

:

To amend the 2015 Share Option Scheme and refresh the scheme mandate limit under the 2015 Share Option Scheme.

501,381,220

(85.77268%)

83,165,305

(14.22732%)

38,275,001

6

Special Resolution

:

To adopt a new memorandum and articles of association of the Company.

622,545,861

(99.96014%)

248,265

(0.03986%)

27,400

 

* Percentages rounded to 5 decimal places

# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

 

As at the date of the AGM, the number of issued shares of Chi-Med was 690,574,765, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolutions proposed at the AGM.

 

About Chi-Med

 

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com /

+852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEEFEWESSEIL
Date   Source Headline
30th Jun 20269:30 amRNSHUTCHMED to Announce 2026 Half-Year Results
29th Jun 20269:30 amRNSAnnouncement on blocklisting six monthly return
25th Jun 20267:00 amRNS-RHUTCHMED Highlights Phase II Data at ESMO
12th Jun 20267:00 amRNS-RHUTCHMED Highlights Sovleplenib Phase III Data
5th Jun 20269:30 amRNSBlock Admission Application
22nd May 20267:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
21st May 202611:00 amRNS-RNMPA approval for ELUNATE with TYVYT
12th May 202612:45 pmRNSAnnouncement on Results of Annual General Meeting
30th Apr 20269:30 amRNSTotal Voting Rights
29th Apr 202611:00 amRNS-RHUTCHMED Announces NDA Acceptance in China
9th Apr 20269:30 amRNS2025 Annual Report and Notice of AGM
9th Apr 20267:00 amRNS-RData to be Presented at AACR Annual Meeting 2026
23rd Mar 20267:00 amRNS-RHUTCHMED Initiates Phase III Trial of HMPL-760
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
9th Mar 20269:30 amRNSUpdate on Licensed Oncology Product in China
6th Mar 20268:30 amRNSDirectorate change
5th Mar 20261:00 pmRNS-RPublication of Form 20-F
5th Mar 202611:00 amRNS2025 Full Year Results and Business Updates
4th Mar 20268:30 amRNS-RHUTCHMED Initiates Global Trial of ATTC Candidate
6th Feb 20268:30 amRNSHUTCHMED to Announce 2025 Final Results
14th Jan 20267:00 amRNS-RPublication of Phase III Results in The Lancet
7th Jan 20267:00 amRNS-RPositive Topline Results of Phase III Trial
5th Jan 20267:00 amRNS-RSurufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
17th Dec 20257:00 amRNS-RHUTCHMED Initiates Development of ATTC Candidate
8th Dec 20257:00 amRNSExpanded NRDL Coverage + CIDL Inclusion in China
28th Nov 20258:30 amRNSTotal Voting Rights
27th Nov 20257:00 amRNS-RHUTCHMED Highlights Data at ESMO and ASH
5th Nov 20257:00 amRNS-REnrollment Complete in SAFFRON Global Phase III
3rd Nov 20257:00 amRNS-RUpdates from R&D Event
23rd Oct 20257:00 amRNS-RHUTCHMED Presents Data at AACR NCI EORTC
21st Oct 20259:30 amRNSVesting of awards under Long Term Incentive Plan
14th Oct 20259:30 amRNSAppointment of Independent Non-executive Director
13th Oct 20257:05 amRNS-RData to be Presented at the 2025 ESMO Congress
2nd Oct 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ESMO
30th Sep 20259:30 amRNSTotal Voting Rights
12th Sep 20257:00 amRNS-RHUTCHMED to Present R&D Updates on October 31 2025
5th Sep 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at CSCO
26th Aug 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase III Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.